Proton Pump Inhibitors

  • Lars Olbe

Part of the Milestones in Drug Therapy MDT book series (MDT)

Table of contents

  1. Front Matter
    Pages I-X
  2. The discovery and development of the proton pump inhibitor

    1. Front Matter
      Pages 1-1
    2. Sven Erik Sjöstrand, Lars Olbe, Erik Fellenius
      Pages 3-20
  3. Mechanism of Action

    1. Front Matter
      Pages 21-21
    2. George Sachs, Björn Wallmark
      Pages 23-45
    3. Björn Wallmark, George Sachs
      Pages 47-59
  4. The Pharmacology of Proton Pump Inhibitors

    1. Front Matter
      Pages 61-61
    2. Jia-Qing Huang, Richard H. Hunt
      Pages 63-78
    3. Enar Carlsson, Niilo Havu
      Pages 79-89
    4. Werner Creutzfeldt
      Pages 91-115
    5. George Sachs, David Scott, David Wecks, Klaus Melchers
      Pages 117-130
    6. Andre Louis Blum, Jan Martinek
      Pages 131-141
    7. Karl-Uwe Petersen
      Pages 143-157
  5. Pharmaceutical considerations

    1. Front Matter
      Pages 159-159
    2. Åke G. Pilbrant
      Pages 161-169
  6. Clinical Experience with Proton Pump Inhibitors

    1. Front Matter
      Pages 171-171
    2. Peter Malfertheiner
      Pages 173-191
    3. Robert T. Jensen
      Pages 205-221
    4. Lars Lundell, John Dent
      Pages 223-235
  7. Socio-economic impact of acid-related diseases

    1. Front Matter
      Pages 237-237
    2. Hans Glise, Bengt Hallerbäck
      Pages 239-247
  8. Back Matter
    Pages 249-254

About this book


Inhibition of the proton pump in the parietal cells has been established as the main therapeutic principle in the treatment of acid-related diseases, such as peptic ulcer and gastro-oesophageal reflux. The proton pump inhi­ bitors are tailored for their purpose. They accumulate in the target cell, are activated by acid and bind strongly to the specific target - the proton pump. The clinical superiority of the proton pump inhibitors is due not only to their high efficacy but also to the long duration of the acid inhibition in comparison with other antisecretory drugs. At present when drug discovery mostly relies on identification and characterization of potential targets by genome research, molecular biology, combinatorial chemistry and automated screening, it seems worthwhile to present the development of the tITst proton pump inhibitor - omeprazol- starting from a chemical structure with an observed antisecretory effect but also severe toxic effects that had to be eliminated. As always, basic and applied research operate luind in hand to optimize the delicate balance be­ tween efficacy and safety of a new drug. This goal often involves time and many different specialists.


diseases drug helicobacter pylori pharmacology quality of life research therapy

Editors and affiliations

  • Lars Olbe
    • 1
  1. 1.Centre for Gastroenterological ResearchUniversity of GöteborgGöteborgSweden

Bibliographic information